FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to new sulphonamide compounds of the structure as follows 
or to its pharmaceutically acceptable salt, wherein a bicyclic aromatic heterocycle consisting of pyridine condensed with benzene; one of Y and Z is CR2d, whereas the other one is a chemical bond; the ring B is (a) mono- or bicyclic aromatic hydrocarbon having 6-11 carbon atoms as circular atoms; (b) 5-11-merous mono- or bicyclic aromatic heterocycle containing carbon atoms and 1-4 heteroatoms specified in oxygen, sulphur and nitrogen atoms; or (c) 4-12-merous mono- or bicyclic non-aromatic heterocycle containing carbon atoms and 1-4 heteroatoms specified in oxygen, sulphur and nitrogen atoms; ring C: benzene, R1: (a) H; (b) C1-C6alkyl, which can be optionally substituted by 1-3 groups specified in halogen, oxo and hydroxy; (c) C3-C7cycloalkyl; (d) C1-C6alkoxy group; or (e) halogen; each of R2a, R2b, R2c and independently represents(a) H; (b) C1-C6 alkyl, which can be optionally substituted by 1-3 groups specified in C1-C6alkoxy group, halogen and hydroxy; (c) C3-C7cycloalkyl; (d) C1-C6alkoxy group; (e) phenyl; (f) 6-merous monocyclic aromatic heterocyclic group containing carbon atoms and 1-4 heteroatoms specified in oxygen, sulphur and nitrogen atoms; (g) 5-merous monocyclic non-aromatic heterocyclic group containing carbon atoms and 1-4 heteroatoms specified in oxygen, sulphur and nitrogen atoms; or (h) halogen, each of R3a, R3b, R3c and R3d independently means (a) H; (b) C1-C6alkyl, which can be optionally substituted by 1-7 groups specified in C3-C7cycloalkyl (wherein cycloalkyl can be optionally substituted by 1 group specified in C1-C6alkyl and C1-C6halogenalkyl), C1-C6alkoxy group, C1-C6halogenoalkoxy, halogen and hydroxy; (c) C3-C7cycloalkyl; (d) C1-C6alkoxy group, which can be optionally substituted by 1-3 groups specified in C3-C7cycloalkyl, C1-C6alkoxy group and halogen; (e) C3-C7cycloalkoxy group; (f) phenyl, which can be optionally substituted by 1 group specified in halogen; (g) 6-merous monocyclic aromatic heterocyclic group containing carbon atoms and 1-4 heteroatoms specified in oxygen, sulphur and nitrogen atoms; (h) phenoxy group; (j) halogen; or (k) hydroxy, each of R5 and R6: H, n means 0 or 1, X is (a) a carboxy group; (b) C1-C6alkoxycarbonyl; (c) hydroxy-C1-C6-alkyl, (d) aminocarbonyl, wherein a nitrogen atom can be optionally substituted by one group specified in C1-C6alkyl, C1-C6alkoxy group and nitrile; or (e) C2-C7alkanoyl. The invention also refers to a pharmaceutical composition based on the declared compound and to using the declared compound.
EFFECT: produced are new sulphonamide compounds possessing TRPM8 antagonist activity.
16 cl, 20 tbl, 242 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HETEROCYCLIC COMPOUNDS AND THEIR APPLICATION AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | 2011 |
|
RU2623427C2 |
| SPIROOXYINDOLE DERIVATIVES AND APPLICATION THEREOF AS THERAPEUTIC AGENTS | 2006 |
|
RU2415143C2 |
| SUBSTITUTED HETEROCYCLIC SULPHONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | 2014 |
|
RU2675792C2 |
| BUPRENORPHINE ANALOGUES | 2009 |
|
RU2520222C2 |
| COMPOUNDS OF THIENYL[3, 2-d]PYRIMIDINE-4-ON, METHOD FOR PRODUCTION, PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION | 2012 |
|
RU2624021C2 |
| PYRIDINES SUBSTITUTED WITH HETEROARYL AND APPLICATION METHODS | 2017 |
|
RU2756743C2 |
| BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (RORγ) AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2789059C2 |
| 2,5-DIOXOIMIDAZOLIN-4-YL METHYLCARBONYL COMPOUNDS, METHOD OF OBTAINING THEM, PHARMACEUTICAL MIXTURES CONTAING THEM AND THIR USE IN MEDICINE PREPARATION | 2003 |
|
RU2326117C2 |
| NOVEL CLASS OF SELECTIVE AGONISTS OF SOMATOSTATIN RECEPTORS | 2014 |
|
RU2603962C2 |
| CONDENSED HETEROCYCLIC COMPOUNDS | 2006 |
|
RU2408586C2 |
